Aldosterone is a critical component of the reninangiotensin-aldosterone system (RAAS) that regulates water-sodium homeostasis and blood pressure (BP), increasing during volume depletion as a compensatory mechanism. The aldosterone excess in patients with primary aldosteronism (PA) leads to an overactivation of the mineralocorticoid receptor (MR) with deleterious effects in different tissues. 1 Inappropriately elevated levels of aldosterone promote left ventricular hypertrophy, atrial fibrillation, and cardiovascular damage 2 (CVD), in addition to obstructive sleep apnea, 3 chronic renal disease with hypertension, increased triglycerides, central obesity, and metabolic syndrome (MetS). 4 These effects of elevated levels of aldosterone that lead to CVD are independent of BP values. Moreover, patients with PA have a higher rate of cardiovascular events than essential hypertensives; however, the role of MetS in the development of these cardiovascular events has been poorly addressed in the literature. 5 Aldosterone has been linked to obesity and MetS. 6,7 Adipocytes produce factors that stimulate aldosterone
secretion from the adrenal gland 8 independently of traditional secretagogues, such as angiotensin II, elevated serum potassium, and adrenocorticotrophic hormone, thus providing a link between adipose tissue, obesity, and aldosterone. Likewise, patients with obesity with restricted salt diets and animal models of diet-induced obesity 9 have shown increased levels of aldosterone 5, 10 that decrease with weight loss. 11 However, the positive association between aldosterone and obesity is under debate, with some studies reporting that it may only be true for women 12 or African American population, 13 whereas others suggesting there may be no association at all. This sex-dependent discrepancy could be partially explained by the hormonal profile during the menstrual cycle that affects aldosterone levels. 14 On the other hand, aldosterone-independent low-renin hypertension (LRH) is more frequent in French Canadian and African American populations, suggesting that the RAAS is regulated by a heterogeneity of factors. 15 MR activation by either aldosterone or cortisol is followed by a decrease in renin. Therefore, the use of renin as the only indicator of aldosterone actions is not appropriate, given that diseases such as severe hypercortisolism, the apparent mineralocorticoids excess, 16 and congenital hypertensive adrenal hyperplasia 17 can also activate the MR. In addition, other pathologies such as LRH have a bimodal aldosterone distribution, 18 suggesting 2 different LRH phenotypes, an aldosterone-dependent LRH (such as PA) with high plasma aldosterone levels and a non-aldosterone-dependent phenotype with lower aldosterone levels. Considering the aforementioned evidence, the aldosterone/renin ratio (ARR) is the recommended screening test for PA, as it has been shown to be more accurate than aldosterone, renin, or potassium alone 1, 19 Besides, the ARR has also proven to be elevated in non-PA pathologies such as polycystic ovary syndrome, 20 suggesting a RAAS dysregulation.
It is clear that overt PA, independent of the influence of BP, is associated with a strikingly higher risk for cardiometabolic outcomes when compared with essential hypertension, but there is scarce information regarding when this damage may begin. At present, milder forms of autonomous and reninindependent aldosteronism have been described with a continuum of autonomous aldosterone secretion with MR activation observed even in healthy normotensives (NTs). 21, 22 The aim of this study was to determine in a Hispanic population without classic PA whether the ARR is associated with MetS as a primary outcome and with cardiometabolic and inflammatory biomarkers as an exploratory outcome.
PATIENTS AND METHODS
We performed a cross-sectional study in a cohort of NT and hypertensive subjects, previously recruited to study causes of endocrine hypertension. The study was approved by the ethics committee of the Faculty of Medicine of the Pontificia Universidad Católica de Chile in accordance with the Declaration of Helsinki. Consent was obtained from all subjects after full explanation of the purpose and nature of all procedures used. Individuals included were recruited from primary care centers in Santiago, Chile. A total of 275 adolescents (documented puberty Tanner > 2, no difference in the renin-aldosterone system in relation to adults 23 ) and adults of both genders were included, under ad libitum sodium diet. All subjects with previously diagnosed secondary causes of hypertension such as PA (ARR > 25 with aldosterone > 16 ng/dl (0.444 nM)), apparent mineralocorticoids excess, hypercortisolism, pheochromocytoma, and renovascular disease were excluded. Subjects using glucocorticoids, spironolactone, or contraceptives containing either estrogen or drospirenone were also excluded, given their known effects on plasma adrenal hormones. Patients using antihypertensive drugs that affect the RAAS, such as β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics, were excluded or switched to amlodipine or doxazosin for at least 4 weeks due to the neutral effect of these on the RAAS. 19 We also excluded subjects with diabetes mellitus, hepatic failure, and under high-dose lipophilic statin therapy.
Participants 25 : waist circumference > 95% for age and sex; >95% for age, sex, and height; TGs >110 mg/dl; HDL cholesterol <40 mg/dl; fasting glucose >100 mg/dl). To perform a sensitivity analysis, MetS was also diagnosed according to the World Health Organization suggestions (WHO criteria 26 ).
Serum fasting lipid profile and glucose concentrations were measured using a Roche-Hitachi Modular automated chemical analyzer (Hitachi, Tokyo, Japan), whereas serum and urinary potassium and sodium were determined through indirect potentiometry. Plasma aldosterone and plasma renin activity (PRA) were measured by immunoassay as described previously. 27 Urinary aldosterone was measured using high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC/MS-MS). The ARR was expressed in conventional units. Values of plasma 9.041 ng/ dl (0.25 nM) or urine 4.612 ng/ml (1.279 nM) aldosterone; renin activity 1.811 ng/ml/hour (0.50 ng/l/s)) and ARR 6.321 of the control group were considered normal. Urinary microalbumin (MAC) was measured using an automatized turbidimetric analysis.
To evaluate the inflammatory state of the patients, the following markers were measured: high-sensitivity C-reactive protein through a nephelometric assay (System BN ProSpec; Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany). Total serum adiponectin (Millipore, Billerica, MA), leptin (Diasource, Nivelles, Belgium), and fasting serum insulin (Siemens, Deerfield, IL) were analyzed by radioimmunoassay using commercial kits. Plasminogen activator inhibitor type 1 (PAI-1; HYPHEN BioMed, France) was evaluated using a commercial enzyme-linked immunosorbent assay kit according to the manufacturer's protocol. Matrix metalloproteinase 9 and 2 activities (MMP-9 and MMP-2, respectively) were estimated by zymography, 28 and the results were expressed relative to an internal control with an inter-assay variation coefficient less than 10% for all parameters analyzed.
Data analysis
Analyses were performed using SPSS, version 20. (SPSS, Chicago, IL). Data for continuous variables are presented as the mean with standard deviation. A bootstrapping procedure with 1,000 iterations was performed for variables without a normal distribution (e.g., PRA and aldosterone). Pearson correlation and adjusted linear regression for age, sex, and body mass index (BMI) were used to evaluate the association between plasma and urinary aldosterone, PRA, or ARR with the primary outcome: MetS. The association between inflammatory and prothrombotic biomarkers was assessed as exploratory outcomes. A logistic regression was performed to evaluate the association of MetS with ARR along with covariates chosen for their clinical importance and significance in univariate analyses. Finally, the discriminative capacity of the logistic regression was reported using the C statistic (area under the receiver-operating characteristic (ROC) curve). Statistical significance was set at P < 0.05.
RESULTS

Baseline characteristics
Baseline features of the 275 selected participants are shown in Supplementary Table 1 . Briefly, the cohort comprised mostly female (72.1%), with a mean age of 35.6 ± 14.8 years and overweight (BMI 27 ± 4.4 kg/m 2 ). Fifty-two percent cohort had hypertensive (HT) according to the report of the American College of Cardiology/American Heart Association Task Force, 29 with a mean systolic blood pressure (SBP) of 127.8 ± 19.6 mm Hg and mean diastolic blood pressure (DBP) of 81.98 ± 13.3 mm Hg.
The serum fasting lipid profile included TG (1.42 ± 0.99 mmol), HDL cholesterol (1.285 ± 0.36 mmol), and LDL cholesterol (2.769 ± 0.922 mmol). Mean plasma and urinary aldosterone levels were in the normal range (9.372 ± 6.523 ng/dl or 0.259 ± 0.181 nM and 5.029 ± 4.49 ng/dl or 1.39 ± 1.24 nM, respectively). The estimated prevalence of MetS was 28% according to the ATP III, 26% according to the WHO criteria, and 21% according to the Cook's criteria.
Association between plasma and urinary aldosterone, PRA, and ARR with MetS and other biomarkers
Our first goal was to investigate the association of plasma or urinary aldosterone, PRA, and ARR with MetS and inflammatory parameters. Correlation analysis of all subject (n = 275) showed that the ARR was positively associated with the number of MetS variables (r = 0.191, P = 0.002), BMI (r = 0.136, P = 0.026), SBP (r = 0.183, P = 0.002), potassium excreted fraction (r = 0.191, P = 0.0014), LDL cholesterol (r = 0.156, P = 0.01), MAC (r = 0.136, P = 0.029), PAI-1 (r = 0.158, P = 0.009), and leptin (r = 0.142, P = 0.019) and negatively associated with MMP-2 activity (r = -0.178, P = 0.003). A positive association was found between PRA and the activity of MMP-9 (r = 0.221, P < 0.0001) and MMP-2 (r = 0.254, P < 0.0001). On the contrary, PRA showed a negative association with MetS (r = -0.122, P = 0.045), BMI (r = -0.193, P = 0.001), fat (r = -0.137, P = 0.028), waist circumference (r = -0.165, P = 0.018), waist/hip ratio (r = -0.165, P = 0.0185), and PAI-1 levels (r = -0.154, P = 0.011). Plasma and urine aldosterone levels were not associated with number of MetS variables or with any inflammatory markers. Plasma aldosterone levels, on the other hand, showed a positive association with HOMA-IR (r = 0.12, P = 0.05), whereas urinary aldosterone levels showed a positive association with leptin (r = 0.142, P = 0.025; Table 1 ).
Adjusted linear regression analysis of PRA and ARR with MetS
The number of MetS variables showed a positive linear correlation with the ARR (r = 0.194, P = 0.002) and a negative correlation with PRA (r = -0.121, P = 0.049). When adjusted by sex, age, and BMI, the correlation with ARR remained significant (partial r = 0.108, P = 0.05) whereas the PRA did not (partial r = 0.015, P = 0.779). Similarly, after adjusting by sex, age, BMI, and urinary sodium, the MetS index showed a positive linear correlation with the ARR (partial r = 0.113, P 0.042; Table 2 ).
Evaluation of ARR according to hypertensive or MetS status
The ARR is mainly used for the screening and diagnosis of PA and is highly sensitive in patients carrying severe HT due to PA, which is a component of MetS. For this reason, the studied cohort was dichotomized into HT or NT and a t-test was performed to compare variables. The HT group had a significantly higher ARR (P = 0.0183) than the NT group (Table 3) . When the cohort was dichotomized by the presence or absence of MetS, the MetS group had a significantly lower PRA (P = 0.0258) and a higher ARR (P = 0.0004) than the non-MetS group (Table 3) . In both cases, the mean values of the ARR were far from the diagnostic cutoff point for PA.
Logistic regression analysis between ARR and MetS according to ATP III or WHO
The ARR showed a highly sensitive association with metabolic and inflammatory variables. For this reason and to further evaluate the relationship between the ARR and MetS, a univariate logistic regression analysis was performed, resulting in an association between the ARR and MetS 1.09 [95% CI =1.036-1.148] P = 0.002. After adjusting for age, BMI, and sex in a multivariate analysis, the ARR remained significant 1.069 [95% CI = 1.011-1.131] P = 0.02 (Table 4) . These results were confirmed by using the WHO criteria for MetS as a sensitivity analysis, with a correlation of 1.086 [95% CI = 1.031-1.143] P = 0.002 for the univariate model and 1.086 [95% CI =1.023-1.152] P = 0.007 for the multivariate model. In contrast, the number of variables of MetS showed no significant correlation with aldosterone or PRA (Table 4) .
ROC curve
To determine if the ARR is associated with MetS, a ROC curve and the area under the curve (AUC) adjusted by age, BMI, and sex were determined. ROC curve analysis showed that the ARR (AUC = 0.754 (0.688-0.819)) was a valuable biomarker of the potential risk of MetS. Abbreviations: ARR, aldosterone/renin ratio; BMI, body mass index; DBP, diastolic blood pressure; HDL-cholesterol, high-density lipoprotein cholesterol; HOMA, homeostasis model assessment of insulin resistance; hs CRP, high-sensitivity C-reactive protein; LDL-cholesterol, low-density lipoprotein cholesterol; MAC, microalbuminuria; MMP-9, matrix metallopeptidase 9; MMP-2, matrix metallopeptidase 2; PAI-I, plasminogen activator inhibitor type 1; PEF, potassium excretion fraction; PRA, plasmatic renin activity; SBP, systolic blood pressure; TG, triglycerides.
In an exploratory analysis, we evaluated whether there was a specific cutoff point in which the ARR could have clinical importance (mainly with low false positives, in the setting of a prevalent disease), and we found in our cohort that an ARR > 16 had an excellent specificity (95%) for MetS, with an expected low sensitivity of 25%.
DISCUSSION
Here, we showed for the first time in a Hispanic population without PA that the ARR is a more sensitive marker for the detection of MetS and MetS-associated endothelial damage than plasma and urinary aldosterone or PRA. Moreover, the ARR but not aldosterone alone was associated with inflammatory and endothelial markers, indicating that an elevated ARR, although below the thresholds defined for PA screening, can be considered as an early marker of cardio-metabolic alterations. This finding, in line with recent evidence, with the ARR predicting future hypertension and clinical PA. 30 We showed that the ARR was positively associated with MetS, BMI, SBP, DBP, and LDL cholesterol (Table 1) , as well as with MetS variables in a linear regression model adjusted by sex, age, and BMI (Table 2) , which was significantly higher in MetS and hypertensive subjects (Table 3) . Similarly, a logistic regression analysis adjusted by sex, age, and BMI showed that the ARR is positively associated with MetS status, whereas the ROC curve analysis revealed that a 10-points increase in the ARR raises by 75% the probability of having MetS. For this, the ARR may be considered as a valuable biomarker of MetS risk. At present, the ARR as a continuous variable has been associated with renin-independent aldosteronism among the healthy and mildly hypertensive population, 22, 30 suggesting a continuous between adrenal hypersecretion and Significance *P <0.05; **P <0.001; ***P <0.0001.
Abbreviations: ARR, aldosterone/renin ratio; HT, hypertensive; MetS, metabolic syndrome ATP III criteria; MS, MetS; NMS, not MetS according ATP III; NT, normotensive; PRA, plasmatic renin activity. associated cardiometabolic risk, rather than a dichotomy between normal/abnormal subjects.
Previously, PA patients have been associated with MetS 31, 32 and glycemia dysregulation. Our data suggest that metabolic alterations could already be present in patients with subtle elevations of the ARR without classic PA. The ARR was positively associated with PAI-1 and MAC, which may be an indication of early organ and endothelial damage in subclinical PA patients. In vivo studies have shown that spironolactone decreases PAI-1 antigen in hypertensive 33 and NT 34 subjects, whereas in vitro studies performed on rat mesangial cells, fibroblast cells, 35 and human mononuclear leukocytes 36 confirmed that PAI-1 expression is induced by aldosterone and prevented by an MR antagonist. 35 Animal models of obesity have shown that MR activation increases the expression of proinflammatory cytokines such as tumor necrosis factor-α, monocyte chemoattractant protein-1, and PAI-1, inducing an inflammatory state that can be prevented using an MR antagonist. 37 Thus, the association of the ARR with PAI-1 and MAC provides further evidence supporting the ARR as an early indicator of the deleterious effects associated with MR activation.
In our cohort of patients, the homeostatic model assesment for insulin resistance (HOMA-IR) was elevated and positively associated with plasma aldosterone, but not urinary aldosterone, ARR, or PRA. On the other hand, leptin levels were found to be on the normal range and positively associated with urinary aldosterone and the ARR, but not plasma aldosterone, which may reflect the leptin-induced increase of oxidative stress that occurs as the result of MR activation. 38, 39 Given that leptin acts as a driver for aldosterone secretion, 40 it is expected that it might be associated with aldosterone concentrations and therefore, with the ARR. In our study, this relationship was only found for urinary aldosterone, suggesting that the ARR detects MetS-associated parameters in nonclassic PA patients without significant elevations of circulating aldosterone. Curiously, the HOMA-IR and leptin levels showed no relationship between them, whereas other pathologies such as diabetes mellitus type 2 have shown such a relationship. This points toward the facts that relationships described for the ARR and MetS parameters might be independent of insulin resistance status.
Insulin resistance, and therefore the homeostatic model assesment for insulin resistance, has been associated with aldosterone levels and with high leptin levels. Although the relationship between adipose tissue and aldosterone production has been widely demonstrated, 41 the analysis of a large cohort of patients failed to show a relationship between regional adiposity and RAAS activity. 42 The fact that in our cohort the ARR was the only marker associated with leptin may reveal a previously missed indicator to predict the response to increased circulating levels of leptin, MetS, and CVD.
We also found a novel negative association of the ARR with MMP-2 activity, which is highly relevant considering that a decrease in MMP-2 impairs angiogenesis, 43, 44 probably due to lower extracellular matrix degradation by collagenases, a prerequisite for tissue remodeling 45 that may lead to impaired tissue repair. Furthermore, the ARR but not aldosterone levels showed a positive association with the potassium excreted fraction (FEK) that has been used previously by our group as a proxy of MR activation. 22, 46, 47 Interestingly, this association occurs in subjects whose renin and aldosterone levels do not fulfill the current requirements to diagnose PA, 19 , therefore, providing initial evidence to support an increased mineralocorticoid activity in patients with MetS in whom mild deleterious effects of aldosterone could be present. A recent communication by Baudrand et al. 22 supports our results suggesting that aldosterone dysregulation occurs as a continuum, starting as a subclinical phenomenon with normotension, and evolves toward the more classical forms of PA, standing against the dichotomic approach of PA diagnostic algorithms.
The strengths of our study include a complete biochemical analysis for the RAAS, inflammatory, and prothrombotic parameters in all subjects studied. An important limitation is the absence of gold standards to define cutoff points for the ARR, 19 for which the definitions used relied on our previously published data and institutional experience. In addition, no longitudinal follow-up of patients was performed, which would be fundamental to determine whether patients with a high ARR indeed develop a higher incidence of adverse cardiovascular and renal outcomes, for which we encourage future studies to address this matter.
In conclusion, the ARR may reflect the convergence between aldosterone, obesity, and MetS, providing an objective measure of the potentially deleterious effects associated with mineralocorticoid activation in subclinical PA.
Perspective
We identified that the ARR appears to be an indicator of MetS and should be taken into account in the analysis of patients with hypertension, and not only during PA screening. An elevated ARR may provide clues of metabolic alterations and endothelial damage in early stages of hypertension or subclinical PA and could be used as an indirect measure of aldosterone-mediated end-organ damage. More studies are necessary to provide accurate and standardized cutoff points for the ARR in subclinical PA. 
